Hong Kong plans to establish a new regulatory authority for medical products by the end of the year, aiming to enhance international trust and speed up the clinical application of drugs and medical devices. The Hong Kong Centre for Medical Products Regulation will focus on primary evaluation to complement the existing framework, intending to protect public health and promote medical innovation. Controller Li Zili emphasized the need for a comprehensively capable authority that serves not just Hong Kong but patients worldwide, stressing the importance of a transparent and scientific regulatory system.
Director Ronald Lam of the Department of Health highlighted Li Zili's practical experience in regulatory affairs and public health, noting his familiarity with international medical products policies. Li's role will be to lead reforms and establish an interdisciplinary scientific team focused on clinical reviews to accelerate international cooperation. Lam expressed confidence in Li's ability to make use of his experience and leadership skills to achieve these goals.
The new authority seeks to build on Hong Kong's unique strategic position in medical products regulation, linking the mainland with the global medical community. By fostering medical reforms and innovations, the centre aims to become a key player in the global healthcare landscape, with the primary evaluation process serving as a cornerstone for enhancing international trust and accelerating the development and application of medical products.